Dossier assessment

Letermovir (CMV prophylaxis after stem cell transplantation) – Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A23-139
Last updated

Report documents

  1. Extract of dossier assessment

    Letermovir (CMV prophylaxis after stem cell transplantation) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 553 kB, EN, not accessible
    DOI-Link
    https://doi.org/10.60584/A23-139_en
  2. Dossier assessment

    Letermovir (CMV prophylaxis after stem cell transplantation) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 1 MB, DE, not accessible
    DOI-Link
    https://doi.org/10.60584/A23-139

Dossier assessment

Indication:

Prophylaxis of cytomegalovirus reactivation and disease in adult cytomegalovirus-seropositive recipients of an allogeneic haematopoietic stem cell transplant

Result of dossier assessment:

Hint of non-quantifiable added benefit

Additional information

Federal Joint Committee (G-BA)

2024-06-06 A G-BA decision was published.

G-BA documents on this decision

Project details

Project no.
A23-139
Commission
Commission awarded on 15.12.2023 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Immune system and infections
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

DOI

https://doi.org/10.60584/A23-139_en

Connected Projects

  1. Dossier assessment

    Letermovir (CMV prophylaxis after kidney transplant) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A23-137
    Last updated

    Status: Commission completed

  2. Addendum

    Letermovir (prophylaxis of CMV reactivation and disease after stem cell transplantation) - Addendum to Project A23-139

    Project no.
    A24-48
    Last updated

    Status: Commission completed

  3. Dossier assessment

    Letermovir (CMV prophylaxis after stem cell transplantation, < 18 years) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A25-67
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form